---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-24-000006"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:02:08.218148+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Exagen reports record AVISE CTD volume of ~137k units, reaffirms FY2023 guidance

## Summary
- Record AVISE® CTD testing volume of approx. 137,000 units in FY2023.
- Cash balance of $36.5M as of Dec 31, 2023; AR approx. $7M.
- Reaffirms FY2023 revenue guidance of at least $50M, non-GAAP adjusted EBITDA of approx. -$20M.
- Management points to streamlined operations and revamped expense structure toward profitability.

## SEC filing metadata
- accession: 0001274737-24-000006
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473724000006/0001274737-24-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473724000006/exdx-20240107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-24-000006
- JSON: https://secwatch.observer/filing/0001274737-24-000006.json
- Plain text: https://secwatch.observer/filing/0001274737-24-000006.txt

## Key facts
- Earnings Releases
  EXAGEN INC. updated its the full year ended December 31, 2023 guidance (reaffirmed).
  - Period: the full year ended December 31, 2023
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announces select preliminary unaudited financial results for the full year ended December 31, 2023, and reaffirms its full-year 2023 financial guidance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473724000006/0001274737-24-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.